Recent developments include equity financings, clinical progress of FHD-909 in Phase 1 trials, strategic shifts in pipeline focus, and board changes.

• In January 2026, Foghorn completed an equity financing including common stock and pre-funded warrants, raising approximately $50 million gross proceeds [N1].
• The company continues enrollment in Phase 1 trials of FHD-909, a selective SMARCA2 inhibitor for NSCLC and SMARCA4 mutated cancers, with promising preclinical data supporting combination therapies [N4][N5].
• Foghorn discontinued development of FHD-286 for AML in December 2024 to focus on its proprietary pipeline and collaborations [N6].
• Foghorn announced participation in major healthcare conferences in 2025 to highlight its pipeline and strategic objectives [N2].
• The company elected Neil Gallagher, M.D., Ph.D., and Stuart Duty to its Board of Directors in May 2025 [N3].

Foghorn’s proprietary platform and pipeline targeting the chromatin regulatory system represent a novel therapeutic approach with potential to address significant unmet needs in oncology. The strategic collaboration with Eli Lilly enables shared development and commercialization efforts, potentially accelerating clinical progress and market access. The company’s recent equity financings and strong liquidity position support ongoing research and development activities. Positive clinical data from Phase 1 trials of FHD-909 and other programs could validate the platform’s potential and expand the pipeline’s value. The company’s ability to selectively target challenging oncology targets with diverse small molecule modalities may enable differentiated therapies.

Foghorn faces risks typical of clinical-stage biotechnology companies, including the uncertainty of clinical trial outcomes and regulatory approvals. The discontinuation of FHD-286 for AML highlights development risks and the need to focus resources. The company has incurred significant operating losses historically and depends on continued financing and collaborations to fund operations. Competition in oncology drug development is intense, and the novel nature of targeting the chromatin regulatory system may present scientific and technical challenges. The company’s reliance on its collaboration with Eli Lilly introduces dependency risks. Failure to achieve regulatory approvals or commercial success could adversely impact the company’s prospects.

Foghorn Therapeutics’ moat derives from its proprietary Gene Traffic Control platform, which provides a unique integrated and mechanistic understanding of the chromatin regulatory system, a novel and complex therapeutic target implicated in approximately half of all cancers. The company’s ability to study and drug this system at scale and in context is differentiated. Its strategic collaboration with Eli Lilly provides access to development and commercialization resources, cost-sharing, and potential milestone and royalty revenues. The company’s focus on challenging oncology targets with selective small molecule modalities and its biology-first approach further contribute to its competitive positioning. Intellectual property protections and trade secrets around its platform and pipeline add to barriers to entry.

• Clinical and Regulatory Risk: The company’s product candidates are in early clinical stages, and there is uncertainty regarding successful trial outcomes and regulatory approvals.
• Financial Risk: Foghorn has incurred significant operating losses and depends on equity offerings, collaborations, and licensing arrangements to fund operations.
• Collaboration Risk: The strategic collaboration with Eli Lilly is critical to development and commercialization; changes or termination could impact progress.
• Scientific and Technical Risk: Targeting the chromatin regulatory system is novel and complex, with potential challenges in drug discovery and development.
• Market and Competitive Risk: The oncology therapeutics market is highly competitive with many companies pursuing similar targets and modalities.

• Foghorn Therapeutics Inc. is a clinical-stage precision therapeutics biotechnology company focused on developing medicines that target the chromatin regulatory system to treat serious diseases, primarily oncology.
• The company’s proprietary Gene Traffic Control platform enables integrated and mechanistic understanding of chromatin regulatory system components to identify and drug targets.
• Foghorn is working on more than seven programs with one clinical-stage drug candidate, FHD-909, currently in Phase 1 development targeting SMARCA2 (BRM) and SMARCA4 mutated cancers.
• The company uses a small molecule modality agnostic approach including protein degraders, allosteric enzymatic inhibitors, and transcription factor disruptors.
• Foghorn has a strategic collaboration with Eli Lilly and Company initiated in December 2021, including a $300 million upfront payment and an $80 million equity investment by Lilly.
• Under the Lilly collaboration, Foghorn leads discovery and early research, while Lilly leads development and commercialization with a 50/50 cost and profit share in the U.S. for joint programs.
• FHD-909 was transitioned to Lilly in Q3 2023, triggering cost-sharing arrangements.
• Foghorn discontinued development of FHD-286 for AML in December 2024 to focus on proprietary pipeline and collaborations.
• The company raised approximately $102.8 million net proceeds from a May 2024 equity offering and approximately $50 million gross proceeds from a January 2026 offering including common stock and warrants.
• As of September 30, 2026, Foghorn had $80.3 million in cash and cash equivalents, current assets of $158.3 million, current liabilities of $37.3 million, a current ratio of 4.24, and a cash ratio of 2.15.
• For the quarter ended September 30, 2026, Foghorn reported net income of $58.15 million and basic and diluted EPS of $0.81 and $0.80 respectively.
• Foghorn has incurred significant operating losses historically but reported net income in the latest quarter.
• The company leases approximately 72,846 square feet of office and laboratory space in Watertown, MA, with lease term through September 2035 and options to extend.
• Foghorn’s Board of Directors and Audit Committee oversee enterprise risk management including cybersecurity risks, with dedicated IT leadership experienced in biotechnology cybersecurity.
• The company has approximately 21 holders of record of common stock as of February 27, 2026.
• Foghorn participates in major healthcare conferences and has recently added new members to its Board of Directors.
• The company’s research and development expenses include personnel, third-party contractors, manufacturing costs, laboratory supplies, and facilities expenses, tracked on a program basis where possible.
• Foghorn’s ability to generate product revenue depends on successful development and commercialization of product candidates, with no products currently approved for sale and no revenue from product sales to date.